For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
As of close of business last night, CRISPR Therapeutics AG’s stock clocked out at $43.45, up 2.74% from its previous closing price of $42.29. In other words, the price has increased by $2.74 from its previous closing price. On the day, 2.08 million shares were traded.
Ratios:
To gain a deeper understanding of CRSP’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 22.07 and its Current Ratio is at 22.07. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Evercore ISI on February 14, 2025, Upgraded its rating to Outperform and sets its target price to $99 from $60 previously.
On February 12, 2025, TD Cowen Upgraded its rating to Hold which previously was Sell but kept the price unchanged to $35.
On February 03, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $65.H.C. Wainwright initiated its Buy rating on February 03, 2025, with a $65 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 26 ’25 when Greene John bought 7,000 shares for $44.85 per share. The transaction valued at 313,948 led to the insider holds 7,000 shares of the business.
Kulkarni Samarth sold 18,360 shares of CRSP for $1,013,564 on Feb 19 ’25. The Chief Executive Officer now owns 171,613 shares after completing the transaction at $55.20 per share. On Feb 18 ’25, another insider, Kulkarni Samarth, who serves as the Chief Executive Officer of the company, sold 11,640 shares for $55.05 each. As a result, the insider received 640,782 and left with 196,901 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 99.89 while its Price-to-Book (P/B) ratio in mrq is 1.93.
Stock Price History:
Over the past 52 weeks, CRSP has reached a high of $84.17, while it has fallen to a 52-week low of $36.52. The 50-Day Moving Average of the stock is 2.46%, while the 200-Day Moving Average is calculated to be -11.48%.
Shares Statistics:
A total of 85.74M shares are outstanding, with a floating share count of 82.08M. Insiders hold about 4.31% of the company’s shares, while institutions hold 69.39% stake in the company.
Earnings Estimates
Currently, 19.0 analysts are dedicated to thoroughly evaluating and rating the performance of CRISPR Therapeutics AG (CRSP) in the stock market.The consensus estimate for the next quarter is -$1.28, with high estimates of -$0.86 and low estimates of -$1.78.
Analysts are recommending an EPS of between -$2.91 and -$6.94 for the fiscal current year, implying an average EPS of -$4.96. EPS for the following year is -$3.92, with 22.0 analysts recommending between $3.95 and -$7.69.
